RAB25 and neoplasm: In summary, we have shown loss of RAB25 expression in tumor samples, an association between low RAB25 expression and poor clinical outcome, and a reduction in cell migration and increased sensitivity to cisplatin sensitivity in RAB25 overexpressing cells.